38m agoInvesting.com Analyst RatingsBULLISH 58Analyst
UBS reiterates BridgeBio stock rating on strong Attruby sales
UBS reiterates BridgeBio stock rating on strong Attruby sales
Why Is BRIDGEBIO PHARMA INC (BBIO) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 12 wire stories
BRIDGEBIO PHARMA INC (BBIO) is drawing unusual attention today. Our newswire has captured 12 stories on BBIO across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for BBIO publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
BBIO by the numbers
7 sessions: +7.07%Coverage: 12 stories / 7 sourcesAI sentiment: 62/100 (bullish)
The headlines behind the move
1h agoThe FlyBULLISH 61Analyst
BridgeBio Pharma price target raised to $88 from $87 at Morgan Stanley
1h agoThe Motley FoolBULLISH 74Earnings
BridgeBio (BBIO) Q3 2026 Earnings Call Transcript
Revenue surged to $353.2 million as Attruby gains traction in rare disease markets.
2h agoThe FlyBEARISH 38Analyst
BridgeBio Pharma price target lowered to $100 from $110 at TD Cowen
11h agoGuruFocusBULLISH 74Earnings
BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record $1.5 Billion Cash Position and Near-Profitability
14h agoGuruFocusBULLISH 74Earnings
BridgeBio Pharma (BBIO) Reports Q3 2026 Revenues Surge, FDA Priority Review for Infigratinib
14h agoSeeking AlphaBULLISH 64Earnings
BridgeBio signals 3 launches in next 7 months with BBP-418 November 27 PDUFA and infigratinib February 4, 2027 PDUFA
BridgeBio Q3 2026 earnings highlight Attruby growth, strong cash, and key FDA catalysts ahead.
14h agoSeeking AlphaNEUTRAL 50Earnings
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDTCompany ParticipantsChinmay Shukla - Senior Vice President of Strategic...
19h agoSeeking AlphaBULLISH 74Earnings
BridgeBio Pharma GAAP EPS of -$0.42 beats by $0.17, revenue of $353.17M beats by $57.42M
BridgeBio Pharma beat Q3 EPS and revenue estimates as sales surged 192.6% year over year.
19h agoThe FlyBULLISH 68Earnings
BridgeBio Pharma reports Q3 EPS (42c), consensus (56c)
Frequently asked questions
Why is BBIO stock moving today?
BRIDGEBIO PHARMA INC (BBIO) is drawing unusual attention today. Our newswire has captured 12 stories on BBIO across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100). The most recent driver: "UBS reiterates BridgeBio stock rating on strong Attruby sales" (Investing.com Analyst Ratings).
Is BBIO a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of BBIO coverage reads 62/100 over 12 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is ATEC down today (-36.02%)
- Why is INTC down today (-28.29%)
- Why is RDDT down today (-28.16%)
- Why is CDNA up today (+23.45%)
- Why is RBLX down today (-19.54%)
- Why is CACC down today (-19.24%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BBIO: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.